Stem Cell Clinic

Toughest for Tamil Nadu patients to get donor stem cells

By Stem Cell Medicine

CHENNAI: It is harder for natives of Tamil Nadu to find a matching donor for a stem cell transplant compared to other states in the country. The suspected villain: Their genes.

A study published recently in British medical journal 'The Lancet' found that the likelihood of finding a matching stem cell donor for patients with blood-related problems in Tamil Nadu is 44.2% provided the registry had 10 lakh donors. The situation is the opposite in Haryana, with people in that state having the best chances (81.2%) of finding a donor.

Experts say consanguineous marriages are to blame. Consanguineous marriages increase the chances of patients finding a match within their small community but limit the possibility of finding one from a general donor pool.

"Unlike in other countries, stem cell variation in India is complex and dependent on ethnic variation," said Dr Dolly Daniel, professor of the department of transfusion medicine at Christian Medical College, Vellore, who was party of the study team. "Our aim was to find the size and genetic composition of each region and its impact on the proportion of patients who will be able to ?nd a suitable match."

She said Tamil Nadu could be at the tail-end of the list of states they surveyed because of inbreeding and a limited number of donors.

Stem cells are used to regenerate and repair diseased or damaged tissues. Adult stem cells are drawn from bone marrow, blood and the umbilical cord and are used to treat blood-related ailments like leukemia, thalassemia and as well as immunodeficiency.

The possibility of finding a matching stem cell donor within the family is around 30%.

"Finding a matching stem cell donor for the remaining 70% is a complex process. Most seek a graft from registries of unrelated adult donors or banked umbilical cord blood units," said Dr P Srinivasan, co-founder and chairman of Jeevan Stem Cell Bank.

Although the India stem cell industry is estimated to touch $540 million (Rs 3,250 crore) by 2015, the study noted that in terms of the number of donors, India has lagged in meeting demand. The study surveyed 10 adult donor and umbilical cord bank registries and clinical transplant centres in India and studied stem cells of 26 239 individuals.

The possibility of finding a perfect match within India is an average of 14.4% for a registry size of 25,000 and touches 60.6% for a size of 10 lakh. Registries in the country currently have around 1 lakh donors. The study said only when Indian registries have more than 2 lakh donors would patients have a good chance of finding the right match.

The rest is here:
Toughest for Tamil Nadu patients to get donor stem cells

STEM CELL FINDING WELL-NOTED IN LA JOLLA STEM CELL FINDING SHOWS PROMISE

By Uncategorized

By Bradley J. Fikes U-T5:05 a.m.Nov. 12, 2014

A rat model of Parkinsons disease has been successfully treated with neurons derived from human embryonic stem cells, according to a new study led by Swedish scientists.

Its a promising sign for scientists at The Scripps Research Institute and Scripps Health who hope to perform similar therapy on Parkinsons patients using artificial embryonic stem cells.

In rats and people, neurons that make the neurotransmitter dopamine are essential for normal movement. Parkinsons destroys those cells, leading to the movement difficulties that characterize the disease.

Researchers transplanted dopamine-producing cells grown from human embryonic stem cells into the brains of rats whose own dopamine-making neurons had been destroyed. Within five months, the transplanted cells boosted dopamine production to normal levels, restoring normal movement in the rats.

The study was published Thursday in the journal Cell Stem Cell. The senior author was Malin Parmar of Lund University in Sweden.

The results support the Scripps approach of using artificial embryonic stem cells called induced pluripotent stem cells, or IPS cells said Jeanne Loring, head of the Center for Regenerative Medicine at Scripps Research. Loring and the Scripps Health network are part of a group called Summit 4 Stem Cell thats raising funds to treat eight Parkinsons patients with their own IPS cells.

Particularly significant is the studys comparison of the effects of dopamine-making neurons derived from fetal cells to those of embryonic stem cells, Loring said by email.

In the 1980s and 1990s, there were several clinical trials that showed that grafts of fetal brain containing the precursors of dopamine neurons could reverse the effects of Parkinsons disease in some patients, Loring said. We and the others developing stem cell therapies based our plans on the results of those studies, but no one had ever directly compared fetal tissue and human pluripotent stem cell-derived dopamine neurons in an animal model of (Parkinsons).

Induced pluripotent stem cells appear to have much the same capacity as human embryonic stem cells to generate different tissues and organs.

See original here:
STEM CELL FINDING WELL-NOTED IN LA JOLLA STEM CELL FINDING SHOWS PROMISE

STEM CELL FINDING WELL-NOTED IN LA JOLLA

By Uncategorized

By Bradley J. Fikes U-T5:08 a.m.Nov. 12, 2014

A rat model of Parkinsons disease has been successfully treated with neurons derived from human embryonic stem cells, according to a new study led by Swedish scientists.

Its a promising sign for scientists at The Scripps Research Institute and Scripps Health who hope to perform similar therapy on Parkinsons patients using artificial embryonic stem cells.

In rats and people, neurons that make the neurotransmitter dopamine are essential for normal movement. Parkinsons destroys those cells, leading to the movement difficulties that characterize the disease.

Researchers transplanted dopamine-producing cells grown from human embryonic stem cells into the brains of rats whose own dopamine-making neurons had been destroyed. Within five months, the transplanted cells boosted dopamine production to normal levels, restoring normal movement in the rats.

The study was published Thursday in the journal Cell Stem Cell. The senior author was Malin Parmar of Lund University in Sweden.

The results support the Scripps approach of using artificial embryonic stem cells called induced pluripotent stem cells, or IPS cells said Jeanne Loring, head of the Center for Regenerative Medicine at Scripps Research.

Loring and the Scripps Health network are part of a group called Summit 4 Stem Cell thats raising funds to treat eight Parkinsons patients with their own IPS cells.

Particularly significant is the studys comparison of the effects of dopamine-making neurons derived from fetal cells to those of embryonic stem cells, Loring said by email.

In the 1980s and 1990s, there were several clinical trials that showed that grafts of fetal brain containing the precursors of dopamine neurons could reverse the effects of Parkinsons disease in some patients, Loring said. We and the others developing stem cell therapies based our plans on the results of those studies, but no one had ever directly compared fetal tissue and human pluripotent stem cell-derived dopamine neurons in an animal model of (Parkinsons).

Read more here:
STEM CELL FINDING WELL-NOTED IN LA JOLLA

Study Identifying Cell of Origin for Large, Disfiguring Nerve Tumors Lays Groundwork for Development of New Therapies

By Stem Cell Medical Center

Contact Information

Available for logged-in reporters only

Newswise DALLAS November 11, 2014 UTSouthwestern Medical Center researchers have determined the specific type of cell that gives rise to large, disfiguring tumors called plexiform neurofibromas, a finding that could lead to new therapies for preventing growth of these tumors.

This advance provides new insight into the steps that lead to tumor development and suggests ways to develop therapies to prevent neurofibroma formation where none exist today, said Dr. Lu Le, Assistant Professor of Dermatology at UTSouthwestern and senior author of the study, published online and in Cancer Cell.

Plexiform neurofibromas, which are complex tumors that form around nerves, occur in patients with a genetic disorder called neurofibromatosis type 1 (NF1), which affects 1 in 3,500 people. About 30 percent of NF1 patients develop this type of tumor, which is typically benign.

NF1 patients with plexiform neurofibromas, however, have a 10 percent lifetime risk of the tumors developing into malignant peripheral nerve sheath tumors (MPNSTs), a deadly, incurable type of soft-tissue cancer. In addition, due to their unusual capacity for growth, plexiform neurofibromas can be life-threatening by their physical impairment of vital organs or neural function.

While there are no currently approved therapies for either MPNSTs or plexiform neurofibromas, Dr. Le said determining the cell type and location from which these tumors originate is an important step toward discovering new drugs that inhibit tumor development.

If we can isolate and grow the cells of origin for neurofibromas, then we can reconstruct the biological steps that lead these original cells to tumor stage, said Dr. Le, a member of the Harold C. Simmons Cancer Center. Once we know the critical steps in the process, then we can design inhibitors to block each step in an effort to prevent or slow tumor formation.

Using a process called genetic labeling for cell fate tracing, researchers determined that plexiform neurofibromas originate from Schwann cell precursors in embryonic nerve roots.

This study addresses a fundamental question in the neurofibromatosis field, Dr. Le said. It points to the importance of stem cells and their immediate progenitors in the initiation of tumors, consistent with the notion that these neoplasms originate in a subset of primitive precursors and that most cells in an organ do not generate tumors.

Read more from the original source:
Study Identifying Cell of Origin for Large, Disfiguring Nerve Tumors Lays Groundwork for Development of New Therapies

Global Stem Cells Group Announces Plans to Hold Four International Symposiums on Stem Cells and Regenerative Medicine …

By Uncategorized

MIAMI (PRWEB) November 11, 2014

GlobalStemCellsGroup, Inc. has announced plans to host a minimum of four international symposiums on stem cell research in 2015. The symposiums will be held in three Latin American countriesChile, Mexico and Colombiain which Global Stem Cells has established state-of-the-art stem cell clinics staffed with expert medical personnel trained in regenerative medicine, through the Regenestem Network.

The fourth symposium will be held in Miami.

The decision follows the success of the Global Stem Cells Groups first International Symposium on Stem Cells and Regenerative Medicine, held Oct. 2, 3 and 4 in Buenos Aires, Argentina. Global Stem Cells Group CEO Benito Novas says the Buenos Aires event, combined with its steady growth of new clinics throughout Latin America, has provided additional motivation to schedule more stem cell symposiums in an effort to further educate the medical community on the latest advancements in stem cell therapies.

Thanks to Global Stem Cells Groups growing network of world-class stem cell researchers, treatment practitioners and investors committed to advancing stem cell medicine, the company is rapidly moving closer to its goal of helping physicians to bring treatments into their offices for the benefit of patients.

More than 900 physicians, researchers and regenerative medicine experts from around the world attended the Buenos Aires symposium, and Novas expects that number to grow with upcoming conferences.

We will continue to bring together a variety of committed stem cell advocates from the U.S., Mexico, Greece, Hong Kong and other regions around the globe, to be joined by a team of knowledgeable speakers, each one presenting the future of regenerative medicine in their field of specialty, Novas says.

Regenerative medicine as a field is still in its infancy, according to Global Stem Cell Group President and CEO Benito Novas.

Our objective is to [open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point of care medicine to the best of out abilities, Novas says. Our mission is to bring the benefits of stem cell therapies to the physicians office safely, efficacy and compliance with the highest standards of care with safety, efficacy and complying with the highest standard of care the world has to offer.

The purpose of each symposium is to bring top stem cell scientists together to share their knowledge and expertise in regenerative medicine, and begin the process of separating myths from facts when it comes to stem cell science and technology.

Read more:
Global Stem Cells Group Announces Plans to Hold Four International Symposiums on Stem Cells and Regenerative Medicine ...

Stem cell treatment for Rafas back problem

By Stem Cell Treatment

BARCELONA, SpainRafael Nadals doctor says the 14-time Grand Slam winner will receive stem cell treatment on his ailing back.

Angel Ruiz-Cotorro told The Associated Press by phone on Monday that we are going to put cells in a joint in his spine next week in Barcelona.

The Spanish tennis star was already sidelined for the rest of the season after having his appendix removed last week.

Ruiz-Cotorro, who has worked as a doctor for Nadal for the past 14 years, said Nadals back pain is typical of tennis players and that the treatment is meant to help repair his cartilage and is similar to stem cell treatment Nadal received on his knee last year.

He said Nadal, now 28, is expected to return to training in early December.

Several NFL players and baseball players have received stem cell treatment. Nadals fellow Spaniard Pau Gasol, center of the Chicago Bulls, received stem cell treatment on his knee in 2013.

Nadal experienced severe back pain during the final of the Australian Open in January when he lost to Stanislas Wawrinka.

[Nadal] has a problem typical in tennis with a back joint, he had it at the Australian Open, and we have decided to treat it with stem cells, Ruiz-Cotorro said.

The Mallorca island native has struggled with injuries in recent years. A knee injury caused him to miss several months in 2012. AP

Complete stories on our Digital Edition newsstand for tablets, netbooks and mobile phones; 14-issue free trial. About to step out? Get breaking alerts on your mobile.phone. Text ON INQ BREAKING to 4467, for Globe, Smart and Sun subscribers in the Philippines.

See more here:
Stem cell treatment for Rafas back problem

Stem cell research may lead to cure for Type I diabetes …

By Stell Cell Research

DEAR DOCTOR K: My teenage daughter has had Type 1 diabetes since she was 8 years old. Fortunately, exercise, a good diet and insulin treatments have kept her healthy. I recently heard of a breakthrough at Harvard that might someday cure Type 1 diabetes. Can you explain?

DEAR READER: The research youre referring to was conducted in the Harvard laboratory of Dr. Douglas Melton. Like you, Dr. Melton has a child with Type 1 diabetes. When his child became sick, he redirected his laboratory to the goal of finding a cure.

First, some basics. When we eat, sugar (called glucose) gets absorbed into the bloodstream. Almost every cell in our body needs glucose to function normally. However, the cells prefer a steady level of glucose in the blood not too high, not too low, but just right (like Goldilocks).

To keep the glucose level steady, the pancreas a finger-shaped organ in our abdomen makes insulin. Specifically, when we eat and blood levels of glucose rise, cells in the pancreas called beta cells make insulin. Insulin drives glucose from the blood and into cells throughout the body. This lowers blood levels of glucose.

Type 1 diabetes is an autoimmune disease. For reasons that remain unclear, the immune system attacks and kills beta cells. As a result, people with Type 1 diabetes no longer can make their own insulin. Without insulin treatments, blood glucose levels rise dangerously high, and other damaging changes occur in body chemistry.

People with Type 1 diabetes require insulin every day to remain in good health. The discovery of insulin treatment for diabetes (in part by scientists here at Harvard) was a Nobel Prize-winning accomplishment. But it was not a cure. For years, scientists have dreamed of somehow replacing the beta cells that have been killed by the disease.

The discovery of stem cells cells that have the potential to develop into different types of body cells was exciting for medical research. Among other uses, stem cells theoretically can be coaxed into becoming cells that have been killed by disease like beta cells in Type 1 diabetes. However, until now, no one has figured out a technique for transforming stem cells into beta cells, in the large number required to replace the beta cells killed by the disease.

Dr. Meltons team seems to have accomplished that feat. They have been able to create billions of beta cells from one persons stem cells. When the cells were placed inside diabetic mice, they started making insulin in just the right amounts: Blood levels of glucose were not too high, not too low, but just right.

It will be years before we know if this treatment will work in humans. If it works in the short-run, will it continue to work will the cells truly produce a cure?

So while this research does not represent a cure, it is likely to be a landmark event on the road to a cure.

See original here:
Stem cell research may lead to cure for Type I diabetes ...

Alpha Stem Cell Clinics: Delivering a New Kind of Medicine

By Stem Cell Clinic

4u]6 endstream endobj 637 0 obj >stream Hj0~ Cqv1Xpl%3,QC~:?[>27C 8Bc u6{Wn7:gZk"W8'4 xdtN=$cM0.zuFTu%@"($O~p_7MeLq'{(0KdkJ1PQ?o endstream endobj 638 0 obj >stream HtTMs0WQ qLL{p9L vj>=A0)S^ UM&W:j1NEPk*5x$_uiNz*&Y R8J 5QD!ekV;EF#Nm*U34DxE/`uR[0n@J_"vM[h ~ZNhE& fz#)&~p !RG3m,Abb)OFchQ"y8T_w'i&Ql+a^J-i5wj8)x3nDGM[H,&/m vijH' '60kd7O@r 3Lr8CV2`~`=G,#@lsq:jrq9VBN](`&B2CLOAw endstream endobj 639 0 obj >stream HtTM0+hWC.H=VU@ 0bew8 =d4Ki`ptQ^/@8Xe*lrJvX{dSWBx-b UG#B(/Bpj75GndleCYGN9htl`E *CD)_ qsBF}dov_jF' #0h;IT]MDl#x$~/#:{?^H#i-VwX4DnbFoL91Ms^L|mvZ ]yTZDE{u7w HJ'(/y^[IK+NTky(#WEHX3R;3-$T66-v+D| '*u> endstream endobj 640 0 obj >stream HdSR0+2Y$3 .tt:uaGdr_N%kQNS_U ':a*~UtvhDO]5* q"@j3[l!Zp YlEKU(OvJ%E@:Ka-yXB2vnKl'FA127f:[`e+qwo #XR!Q;~:lD*Rxd| UE;g-C yVA7'ikn7}ji6 8l`: g7L Q8.+@;BA6nZBsKVZr,+>stream HV{t]@6 2!CGf# l^` H6C!Pi"mE E=rl(ZE*"Hswf}oHD3$M_NgZByzzRXd~ 1SDS*+gzXW6,YzUb'q'C" uvIpuHR4?eg]@.)gi+T8!-NNJ6qUGv=nG"j1|gmO:K1yM]=0(vWYXSrOB>Ph/ X0W('aC_c7]dg,IcXCH| p3yMcx HnD/ N4Z>7# .v6c5|?vz:iR1ME@d~kEyO3K'Jz8*C#c-L[z 7!>e+;N(iS!i ztNUZX1]Q[!"$QH.$S|_2E *+CyO|T:5m+5Blne5~ W5:F15qsFkgU5Dyq[89q7qcOD9N+i 5u16Y8Y/b,v]UJLsBn/r6"YS*_0P 31u-6Vim&g^;6" }&,Hig+PDP`)wh-C4h.^r3RTJeo )l[E,n?h*EyER,NKQmr,p$3jrd[3&]^xf;bq|wWVf*;vW+~`aCwHOK}z8{LJLTE BW/ hFvPI-YG04v1@Lnf,.KrjE(f-(1Dk8XW'Gh5JW6/= y$$2_oPb3 "QzHK >oI3 ;BG91v1lxQ+ oYN]w~`X7rsE^S8[F/.AP.e- _Pq~C,M]Mkx@N> Hpdwx ?JbO-:ct2el_do]Vj8:5[ouivpVEYp87N*"nP9*AdUqZHpUn9U8E q3.+|VU>{_u1QQY-]%tW8V@6.`Y*lZ]WKI(''FDMMkZYP>O$4/RmkSn;Igs9wJE-[b(,RjiCZo[[]79*.--*-&NX7I2p^AgNBfgQTCRf]YbYUp~GO0_ms?wsujd2V;(H5s~rp}!}m a.[NSD"*zyZZ#N+aew|Pdo~mD0xX/'~?gur5-lF"t2,{p0:O9oeaMXJ'oDK8vpenH$~!choR|tj|ST&|@ ?TJtz250caozz1uOoiCEm#mgd&d-RTBte>z5Vbm7csUjUka=TyA^Z jjJi ~J1IU-G-Jdhhm&W /;Bvc7?&qY3H +U%ny#y M7qD:G6E^d i7zx7j4,{Vu2*)%$(%$W(r%+"%H6Qg *tG?l$K*VLRh@j2FJl|Y>(9R5z dZSz 9HBi}d 2S`*lC :GNfN6pJqR Mrm: Rmp0;=UV!tns^jY~wEc8G3?q1#uh!96o+OPE)Mb{4y#2psgGx'hdl/p]J0> >%d]t}yU+t?+;N9tf|7y Msk{ uGn/W?L&2+6g` endstream endobj 642 0 obj >stream HyTGz{ET"W4j4 Q{4jbL4"F]:jQ#S{oW_U_7QCzP_tlbLg)Dk~|4CZK5@#z}F$L/&YX;`vv_*v4h0Y#&x` uBRlp8 n!BT1&&1.. Ng-Sr[5uHMdU2WL3k&`r'h0u2(Mep+1NXeMATL`)KVx=Mwes%;"O6k("SeH9QI(VCiFZIDX,3-Us|}}vF-C%_ 4sPD^bS^) K+Oh&{:`V8([Yrv+^dXbf+}o;efhKL};vYL{'p(sTLCQ*LF_nq[eyyDrYNrTPfE93Cqow`;}qOuk"l_ RU&"Ea/-(Y*|X6 Mh4N]nbZbZa/Zc`? Qtqt ExhC7tY9DOy7bx1H};7b&qqMDxQx1c)xT /1?cdLQ3Mh*Ah4[()%Q2e_R R}~4s@)q$ouni*4nLi-i!}aA_pKZKnM }mknGK8r{;;iwV*JYnslA'z:4z5h+oeZ%j 799-QmwN8I{ywN9n|9vu!1 )l"gK8@ "5 #(D#8".!L73L36s37B,6KR|i+|mXVc% 7+]WYiV!^*i3@+R_'E7"H*Dp]+"EUlXE"ZXqAxqQ "QWDH)Hi"]dL%E&rE@"Q,JD(BT*Q-jD qSc89^NmqG}@i pAh-SH3uSI7Hh0 4fKh q4&$LSh*C{>}@G1}B9M/hY4BZDKm&Svnl7v1?jM 0&D sne92wJj)p " @sGDBA)B)hmmvNEi}A:DctNI:E;y'y7Gt.Q%eBIL)tR))2))Q.Q>P!Q1P)Q R%SUS]t]E77I1)2nJM)3b!#e*L49gjM3M6&1I:h:m nF"7N:_:[dnSU_eSY4vt:u&bl6:kV

M- Pp ::zzcbcbcF-hXxLDLdLTw.#|O)>/0300s00K%cJ|?;Va5?O_3~X [;{49]9O.L.+JyU}/S2M(O2C,3/2KWkjUeM @mj,Re*K6Y2CBjR{e'k~Y:uP^W uXTG-uTVuU'=uRWuZ>Tn:#+wDyS>S^/YR||SWT= R VUjBUCpXE&j"U3hU.OVm01S@ZW~K/pvO=vO{ rtE{bL 7E&72M9dbL5M9bQ`Ds$&4)I5M9cYa5Yk.Ls3zsl0WFdbmnn2Mcr]3m%5yygygxx=ywy_q?s r11 Z'xx!rJQ:_`) MZ' 9q `0`I~_/+bs1YX}y=g;e_/72Osef/v{>w|88I)xR[-xKKJ^H~s2eKy,bVz`kq@lXJk p+" h+x+Jd+Jt///K%zI^zi^aPIc/Vpo@$ea2FH%eq2^&D$eLi2]fL%ey2_BY$e,e,!VJY%%T$"$R$Zb$V$^$Q$YR$U$]2dLY'elMYV&edIN%[dK}R(E_A9$rXQ9&SrZY9'\+Q*|!7Nm#w'KoZG%@X( JYxoMAa0( A |(G9GT*]*{*jZ:z>D4D#4GM-m]= >g^>~A!a1q I)iY9yXEX%XeFcVbV#aG"h qGd iHG`-2 [ YFvbry|`/E8C(aqB0'p"('qb8'I$'IqR4'p8kLglt648-Vgd$N+kkkkz9mmA;j']vC?O3Ot:Lt:NtN:Mt:O]t.L5D ]tjkFjFkjk&j&kjktnI7t,4Wwk|-OH=X=*vU]ak:v]]~n`7&vSna[6?WyxSU?// PNi$J@Y+BmR(BZR(UMv (:qq@QGVd*0x^}}_{gs//)p=:#R ittAWd2#=nd#}A.c@B>!g1a8F`$Fa4y8xS00300s;QB~r;N8$Nvq{9;qwt]9q&?9{pOvs6p/}/cr^9MeVY3"S1Ru/}4 " SQvp8v{A=Yazy3$T.0r{jgOx1Gi@lJ3hCE}ipF*Z]96RB/LZnF 5 ]lmjN4tK%"|Z"A$9j;5CT`kfdec9W5MPZFJ;k`wMZ;O"6JxqH(G ?zr.0N*n);w@12KSKk%HRY'd8(4^ umW(p%>s)9WImb%-UlJ*qJ=c:$mm;]H:(h{}j{4UNr&I mfeBN+)kj% "AvwZ*#r!woP C &%pr]/~_W7m6m/M2((ct>tKesjsuzJb~JdlFci9fF2'L)*/FZzi {oMirbN_>{dgwNCJh6O?G[l-*:SlBiTp[e7-LEiw%gkEhj4_qr8;zLGml&f'UXt{5VFI(BxGniv&7(4*9E#k.V/&j14zES"4v| ]d}b.`S:~?Jin!!P@E!5RS'%B]mT=LWKw7X"qNDgk`G, ,+sB3'ks5*5/uzs{55WHvweILIt;=yvW/s]#3EOto~G/L^dlVKFX6l~lB{)Hqr5YKSW`5zI,kSj/~BpHv$?T,]tV[z|)z)Ks|l5n]C~bW/sYUg??1^umdU83'&{l';K%ufB8v)[Kv[$,vPQe}XH@WJDi%xD%$Pi3{ssqU.*r5pOJ^Q|ZAU5W1IA=Avg :3W.rz/ [9S^G3R/3h=[J'P1$T6wEd9(uLFpAE'}L:YQ)7URO{D/SKO?O9^'-)ozq^ >McZQ6H e*d,q [+yRa?J@0:8/o^QU0@$[JeKYA(>=/@!|`^ jwKygJmFdP*x""N>!CxCFh4vS.KYK-+cEd xf(Xm!me"5kk"ePm0v3hL0WE.(KS|T(-JKmr6j0>Q 7a,!9DJtT ><_ v="" ku=""/>

:/%ub ~Y6 "6S4'`yMQ" 6d4c44i idooE3VtU`Qh+ Ma[YSGx54'F V[SU(8|; Rvw2e!^c]CsC:Jp;11!eP8-O---OX8E")FShz9?"6PAF3rOGQXM2C?2^o,dOo$9nHMRt>c2wf)34Jvv82>hrlNtX+#krRMLQgz;aif=~;*rho5bx_/8 by8WzI51C 9 7FExG 5w0/wH$Ec|37a[A7x4N};9T%R.}p~+Cpexi$Wdu&[Ap!D+=`enq6dO[15 D4m:&Pa4J|[vGuhD $a8pqi>J |;Xx[k'Zh2}x]c4~;j?wtPej>5A>1=X@4,B7d*Nj7L&b&6w_HxafsLB6PgVO/uCjPZCt;GK7yCpL0;`yF;wc6bxm1 V~/mj>fe]oy/u>zO{W+iH#cjVog2H>N9`}h*I?OL=G:%wC&kXD7Z6]tPmb0M{P[]1j5?c;&nXC#y'$gq-3c oz_=nO*Dg2IT(+y?lf~Ht-W0F-* j~O3buSowOtGHD U.~? L1[m.zm+sZ@$!R.K7{&F%fH*zph)tmWyXY[/z#]CUw.2^or>+B|x0_~82_,o:X|;>L2#LJ%)A[Fv:)k)I:Qfl.WV_2'O$1AA){pxwW.@^&s* .& }Gwa~sS5WGyb6}uT92|.}~b2yE;} 0rn"@:A>sa,;_dU89iZDYy/s4E,~~NB4H/EdrFqp9/*()wg,5Lddy?Y` i7 ?-@YD]9@i WvEi)r7Lu 5Jf1Zc^l,8.,20>]T0H,HPM=?

j>DMCKpuCWw7?oikE7o6 @W.{uXAHH l6PPD KpT`T)WPyYpjG8=1`*5Q) ?kH@P8^ {*7)6tfjh(F{ra~n&c)r&:;+X!|U(2MCQpJ8{Zti{9:-Yo{uE?K{k|Ca=[LWgNnTn/1~zh v&Cl!)2C!i#d%Ekc%Ms $"[LI*H81IE@oFuB?U=X[f #8^d/:%0n)pW -oyXpJ@MTs^Wf;XsK9Gz5>>u@)$ o}uM|ey`{_;r,[WME]j6Xw=cUF4i{"E9-~EOcW#0`b Otffcq9U0"%R1"TJZu5s{zFzW=>xbmf-e~]?Yz!D^[%s3|s|9>}|b;%KqN[i6uFV]+^&e$~eAAcML4U0u TM4"?RO~lt0w;vj[-)%VQRz3v $@WcI[u-lVq+Z7:SgFn*sS=h0]`HJJ0VB@""zifAG2WM>T;(! x&=8_3.a*tq;lW6Rj@@~87{)*OCg%_xm`'":tqvO/FD}``$&'xh@;J@ h G ,E"!Zb1lYLI,gsuxKX+rnRNm%T8'g 9O>W@_al{B:&R(IA0IsRPtTzm V>U)ER&1xajU-i+n /k=fYlUCiq !E(7-fGcy,9salR7)n;R4X):Zu M n)e(2/2DRg h%Xt>x+xj}XM]VS=7Q}h>Gu3? m& u-=SI:8pk,.=KFqJ~,MZJ;/5|Iz=,lnc*=66u> "?rvvLfL:xRLh-SGg[JLadhD>"{(D`jC0>/ 7VEGL[iP&6Hhy>&=k"|A7Rz/$kJ2AhtEpQ2fOj%xGh9WK1V/?/^P@6 x l6nD^F+K@Sk$U6=t)*|"h1iZ;pk^`G/LHwt5{zAK{%(%ETjD32C:z_>kTa~,

6ow?(!B Jh} CO+M,pny: {tFY=:S8hr2n7j+zSc (|V;g3&oLB}F| /E21xgx)6mk{?Fn7a>J*I%yVlnBe#""T(XxU53#^W&_fp$nBC`h|oKz8b=1::w&AN=3! lsqAc|3Gui}A;6%47S;G /1K/~x)6vPfr s:7;:J_O0o.Ey3gu*MyP,v )p5U~5"?uc"MO0%9&YKXcjt:l uPz@:c%>n%k5qi>/3tb*HL;tuVPhI.;X7.U_S&h&b,l5-{O*2GY"3d'*eVJ_jlVF8Kk::cW@>$_H-2ZnT9g8.[8kQ"H=&oBhGF|}8+>Fe SM&sB8=&<51TuFm?4]`=?!}>7CL.mWCe+J<|M)&)QE~R+}Y|dO#%?ZSy8C"vQ^CGER&)e@'/Fz/~-C uRZEY8Dy}9fT .NmdW!m|dr7}O=D~&3IwTyyv`zTI0v35r8G8a{k~+ag"_.hBndbx^b)d&R#pkH6MBB1PkX;o2J3/Su_2#FZ:LN5 `*hN39xGo@lZ5pV%r~[V.c]-a}wC]Hw?y~yAz6t:n,G <[ PodwEd82s YWg`_E'nQ[`Gsb)TO(>rKz n)UDzX98G?3/V/C!O[1<}PdJ318I~};M&YYk #[9w#X_yS'P^N>)QCDuRz1~qQ$3%e4acsuPKe@}%Z? H2,>/d? d7A=$]|yXbYj$26vw&K])oXZdy:+h.8)2kZP]UiuGWBIjb&`Pj,-LukaU|"2jy%lQ 5c=g99a~!`6r1:2v,zOn27FI83OFmP%/$Y$`3i?;o#H;:>Q}e;2N|o9nUP#FA> M UwJeF:A7yd9!t{{C'+D$3>="e1*:cOy<.ue> <'YoOwSrD$<'UH<7IG$/>.3x{ ~!,gl)ywK_[!)9{[BOG06]xShg/'`602f/Ze9ImGq~ueL(OE.sE55:`k#PF|$~:c#d0T&97bvw1(qxjJ+5f^{e/p>:K o::wO?';%. ]GNZ-u:3.K*No?6p7[-2R%|o 2`k`dnufL 'YgKoz;Ki?T&&^[.."/,`'G^J__HIQ%We38?qzY]] KX5|3@z8yOHI4o&n%^*pG"r{5m 8#^NqoVbcx@t?+ILTwd?U|!>K`1@mH2}HZf+u%;wJ{4TKvk{7qg"g1QZ6Qs|v/Zix3i?I-2^JA9-}(v@Y Dfjq-;$ts%}jYlJ8NS@~GQqo7w F$X L#wI$wpw v!UZa`B[8jNJ~>8H_2}{8y,Hy24mF3[Ic0U`}75uGl;F5P~o0uI}oYim*ka0TJ4zw"z.xmI/w0 Sj7l.`=ws>4}%R>)3b1 -.=aa,m$?/TbhMB 5A4+} DqHF"EKDx]Td8Ic]J7qn|Ozt)qO:;;bW5e?#q},8tBA9>.bUbGB4.gv7{N)L,A!czpg0dTemzn~_XP"`!(]i/Tx;;|vPtFnq{ROc!75cN68cq0gl{?*h$ ycn-/uw) kh>"a:HV;[h[ ZG3%iMS_Bo~&u/D)q^{j(w3|U@/@Fsq;8FLFuK=!J=I8=DQ"(3!(k6QnT6fp~N]Gj|!c|pyH{BfpXuS2*sO9L2)sXCT]e(_Vf2oI}CR[G;n>/uURWJmBjg>%IO@FeRJ}LSNCcZViS.dP`X `/8S~ yZm6hBZVj!Z-DhR bpFm7jQ1@4h. *@1h@R'hKTD[m/Xk-3y @WhGHI+iGTHD4hxlulvjil)e"SL ApQYG22sdK_0~. ddFC|5 gJ/)|1e#te/F{v(.Qt}e*wC>gt]Yl$Ts f+ _NU56mN@(U4JtTz+{nO9h.D@;07^.I`+@u+j$Qnmqut)Hp=(G658g(iEXeJX baThm")>gmJqJ _Q*%:[o5hj{U}i}m"yq58r1-h4:i"m"9*S 9HNCQd1SLK!$ G6q2+r;>M^&[BX^H;sG.BVdHD_"w-tHis.&8nD~k%T$5p*GR kDd|M&Y"M,0~VcoKevz[ SwZqjD/X.q1&qM6XB_,j!83=m-l^)+>BW}~mdXaH1n6>`g6t"$8@ n5uR?C}vOa}'2xVaPv}fcff`51|iN7n5:0H1R_A|&l/v%;UMv*)-u{J/E6H]oSj*7aBZa5i/f;J!nk%Ew7[2CMb[Qy*FyL&YexyF3fdc6o DGyc.!II1YRX/8d Z_#vIwcmy?l@a)ht=q7D[ Zu6a;E"lD7Sq%A.qO_u0pE{pg;mxLI0zA+h q*P Vpl'cg5>/4?)>O7?_q2?G0A>y?y.~/o ~|~;^Z?s|*% endstream endobj 643 0 obj <>stream Hj0 endstream endobj 644 0 obj <>stream HyTSwoc [5laQIBHADED2mtFOE.c}088GNg9w'0Jb 2y.-;!KZ ^i"L0-

Original post:
Alpha Stem Cell Clinics: Delivering a New Kind of Medicine

Minister: Drug administered to Lee Chong Wei by specialist sports clinic

By Stem Cell Clinic

PUTRAJAYA: The banned substance dexamethasone was not administered to Datuk Lee Chong Wei by doctors at the National Sports Institute (ISN) but from a specialist sports clinic as part of a stem cell treatment for his injury.

Youth and Sports Minister Khairy Jamaluddin said it was usual for national athletes to be referred to the Kuala Lumpur-based clinic for specialised treatment such as stem cell procedures.

"There are times when ISN refers our athletes to the private specialist. The doctors at ISN did not administer dexamethasone to the athlete but it was done at the clinic," he said after attending the launch of the GeNexter Carnival 2014 yesterday.

He said the use of dexamethasone was allowed, but only when athletes were "out of competition".

"Many athletes use it outside competition and it usually lasts about 10 days in the system. However, we do not know why it was still in his body," he said.

Chong Wei had reportedly suffered an inner thigh injury and sought stem cell treatment in July.

Last week, Khairy had said that an investigation on the shuttler's medical history revealed that dexamethasone was administered into his body on July 17 to treat his injury.

Chong Wei, 32, pulled out from the Glasgow Commonwealth Games from July 23-Aug 3 to recover from the injury for the Copenhagen World Championships from Aug 25-31.

He was tested positive for dexamethasone during a random doping test at the world meet.

Results of a second test done in Norway had returned positive, resulting in a temporary suspension of Chong Wei pending the outcome of a Badminton World Federation hearing.

Read the original here:
Minister: Drug administered to Lee Chong Wei by specialist sports clinic

Specialist clinic gave Lee banned substance

By Stem Cell Clinic

Putrajaya - The banned substance Dexamethasone was not administered to Malaysian badminton star Lee Chong Wei by doctors at the country's National Sports Institute (ISN), but by a specialist sports clinic in Kuala Lumpur as part of stem-cell treatment for an injury.

This was revealed by Youth and Sports Minister Khairy Jamaluddin yesterday.

"Dexamethasone is allowed for athletes seeking treatment for injuries," he told reporters after attending the launch of the GeNexter Carnival 2014 in Putrajaya.

"It usually lasts in the body for 10 days. But, in this case, we are not sure why it lasted longer than that."

He said that it was the ISN that had referred Lee, the world No. 1, to the clinic.

The shuttler took to Twitter on Saturday, posting a link to an interview in which he describes himself as "devastated" by the allegations.

"Thank you for having faith in me. I never cheated nor will I rely on banned substances," the 32-year-old wrote in the post. "There are so many unanswered questions and I hope to clear my name soon."

Lee - who is facing a suspension of up to two years, which could mean the end of his career - is awaiting a hearing by the Badminton World Federation (BWF). No date has been set.

Referring to the BWF hearing, Mr Khairy said that preparations are being made, with updates to be given in due course.

Lee tested positive for dexamethasone during a random doping test at the World Championships in Copenhagen in August.

Original post:
Specialist clinic gave Lee banned substance

→←